Statistics from Altmetric.com
Hypertrophic cardiomyopathy (HCM) is characterised by a high genetic, pathological and clinical heterogeneity, with an unpredictable natural history, and represents a challenge in terms of diagnosis, risk stratification and management. Although many patients have a benign clinical course, sudden cardiac death (SCD) can occur as the first manifestation of HCM in asymptomatic, often young subjects.1 Ventricular tachyarrhythmias represent the main underlying mechanism of SCD. The myocardial substrate creating arrhythmia susceptibility consists of myocyte disarray and hypertrophy, expansion of interstitial matrix with diffuse fibrosis, and small artery dysplasia responsible for silent microvascular ischaemia and myocyte death, ultimately repaired as replacement fibrosis.2 Although HCM is caused by sarcomere genes mutation, an important component of the phenotypic expression is determined by increased myocardial connective tissue. Different patterns of fibrosis have been described: increase in pericellular and fascicular connective tissue, plexiform fibrosis associated with myocardial disarray, perivascular fibrosis and microscopic replacement scars.3
There is emerging evidence that myocardial fibrosis is an early and fundamental manifestation of HCM, elevated levels of serum C-terminal pro-peptide of type I procollagen indicating increased myocardial collagen synthesis in sarcomere-mutation carriers without overt disease.4 There are data suggesting that myocardial fibrosis may have a pathophysiological role in the occurrence of SCD5 even in patients without conventional risk factors.6 Information about HCM histology is limited to specific phenotypes and stages of the disease, as data derive mainly from ex-vivo studies of patients who died suddenly, or from patients with end-stage disease who underwent heart transplantation.3 ,5
In the implantable cardioverter defibrillator era, increased attention has been given to proper stratification of risk for SCD by identifying more accurate clinical markers since conventional risk factors for SCD have a very low positive predictive value.1 Therefore, in vivo imaging of myocardial fibrosis by contrast-enhanced …
Contributors BAP initiated and designed this article. Both authors contributed to the writing of the article and approved the final manuscript.
Funding This work was supported by a grant of the Romanian Ministry of National Education, CNCS- UEFISCDI, project number PN-II-ID-PCE-2012-4-0560 (contract 21/2013), and by a grant of the University of Medicine and Pharmacy ‘Carol Davila’ (contract 28329/2013).
Competing interests BAP has received research support and lecture honoraria from General Electric Healthcare.
Provenance and peer review Commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.